Oral GLP-1 agonist Elecoglipron evaluated in Phase 2b trial for type 2 diabetes

Current type 2 diabetes management often relies on injectable glucagon-like peptide-1 receptor agonists (GLP-1 RA) which, despite their efficacy, can present adherence challenges for patients. Oral small molecule GLP-1 RAs offer a promising alternative, potentially improving patient convenience and compliance by eliminating the need for injections. This approach aims to maintain the robust glycemic control and weight management benefits associated with GLP-1 agonism while addressing a significant barrier to long-term therapy.

This multicenter, phase 2b, randomized, double-blind, placebo-controlled trial enrolled adults aged 18 years or older with type 2 diabetes (HbA1c ≥7.0% to ≤10.5%, BMI ≥23 kg/m2) managed with diet/exercise, metformin, or an SGLT2 inhibitor. Participants were randomized to receive Elecoglipron as oral once-daily tablets without dose escalation (5, 15, or 25 mg) or with dose-escalation regimens targeting 50 mg (every 2-week escalation) and 75 mg (every 2-week or 4-week escalation). Control arms included placebo (matched to each Elecoglipron group) or open-label oral semaglutide titrated to 14 mg once daily for 26 weeks. The primary endpoint was percent change in HbA1c from baseline to 26 weeks.

The SOLSTICE trial systematically assessed the efficacy, safety, and tolerability of Elecoglipron across various once-daily oral dosing regimens over 26 weeks. The primary endpoint, percent change in HbA1c from baseline, was evaluated to determine the glycemic control achieved by Elecoglipron compared to placebo and open-label oral semaglutide. Safety and tolerability profiles were also comprehensively assessed across all treatment arms. Specific quantitative results regarding HbA1c reductions, statistical significance, or detailed adverse event rates are not provided in this abstract, but the study design indicates a thorough evaluation of these parameters.